In an open letter published in the New York Times, former CDC directors call on Congress to mitigate threats to public health caused by mass layoffs and cuts to critical programs. 

The Varipulse PFA platform, which has already received FDA and CE mark approval, was linked to an adverse event rate of just 0.6%. 

New data out of ESC Congress 2025 suggest care teams can take a more minimalist approach during a majority of TAVR cases and only treat patients with local anesthesia. In some cases, however, sedation will still be necessary. 

Leqembi (lecanemab) was approved by the FDA in 2023. It is an infusion drug that has been shown to reduce Alzheimer’s-related cognitive decline by up to 27%. 

A new analysis published in Artificial Intelligence in Medicine argues that education tools are failing to show clinicians how to make use of new technologies, calling into question the benefit of rapid adoption. 

Multiple lots of extended tip applicators from Integra LifeSciences could put patients at risk of serious infection, prompting the FDA to designate the recall as Class I.

A new report reveals that states are keeping databases on “imposter nurses” to slow what could be a growing trend of unlicensed individuals holding nursing positions at hospitals nationwide. 

OpenAI, the developer of ChatGPT, has made a couple of big hires as it prepares for a major expansion into healthcare.